Full Description
Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality.
This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity.
Contents
Section I: General Considerations
1. Epidemiology and Trend of Prognosis in Cancer Patients
2. Categories of Anticancer Treatments
3. Classification by Mechanisms of Cardiotoxicity
4. Cardiotoxicity of Oncologic Treatments: Is There a Uniform Definition?
5. The Impact of Radiotherapy
Section II: Detrimental Effects of Anticancer Drugs and Radiotherapy on the Heart
6. Lessons From Preclinical Models
7. Genetic and Epigenetic Risk Factors
8. Changes of Myocardial Structure and Function
9. Alteration of Heart Valves
10. Pericardial Damage
11. Effects of Radiotherapy on Vessels and Coronary Arteries
12. Cardiac Conduction Disturbances
Section III: Cardiovascular Complications of Cancer Treatments
13. Cardiac Rhythm Disturbances
14. Acute and Chronic Heart Failure
15. Coronary Artery Disease
16. Pericardial Effusion and Pericarditis
17. Radiation-Induced Carotid Atherosclerosis
18. Valvular Heart Disease
19. Atrial Fibrillation and Stroke in Cancer Patients
Section IV: Imaging Evaluation of Cardiac Structure and Function in Cancer Patients
20. The Role of Echocardiography
21. The Role of Cardiovascular Magnetic Resonance (CMR)
22. Nuclear Medicine Imaging and Cardiotoxicity
Section V: Detection of Cardiac Dysfunction and Predictors of Cardiotoxicity
23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography
24. The Role of Biomarkers: Troponins, BNP, MPO, and Other Biomarkers
25. Screening and Comprehensive Follow-Up Evaluation
26. Preoperative Assessment for Noncardiac Surgery
Section VI: Cardiotoxicity in Childhood
27. Cardiotoxicity of Childhood Cancer Treatments
Section VII: Management of Anticancer Drugs Related Cardiotoxicity
28. Nonpharmacologic Therapy
29. Beta-Blockers
30. Angiotensin-Converting Enzyme Inhibition
31. Diuretics
32. Antiarrhythmic Drugs
33. Anticoagulation in Cancer Patients
34. New Drugs: The Beneficial Effects of Ranolazine
35. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients
36. Focus on the Patient With Known Cardiac Disease
37. Multidisciplinary Approach to Cardiac Disease in Cancer Patients
Section VIII: Future Research Priorities
38. Pharmacogenomics Screening
39. Cardiac Monitoring During Clinical Trials
40. Preventive Therapy
41. Cardiotoxicity: Future Research Directions
